Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals Inc (NQ: ELDN )

4.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Enrollment Completed Four Months Ahead of Schedule 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
80 Participants (Two-thirds of Projected Recruitment) Enrolled 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets. 
Via InvestorPlace
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly. 
Via InvestorPlace
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ... 
Via Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.